Table 2.
Operative features
| Feature | Total study population (N = 119) |
|---|---|
| Preoperative chemotherapy | 119 (100%) |
| Total no. of lines | |
| 1 | 87 (73%) |
| >1 | 32 (27%) |
| Total no. of cycles | |
| <6 | 27 (24%) |
| ≥6 | 85 (76%) |
| Regimen last preoperative line | |
| 5-FU LV | 32 (27%) |
| 5-FU LV oxaliplatin | 61 (51%) |
| 5-FU LV irinotecan | 18 (15%) |
| Other | 8 (7%) |
| Chronomodulated delivery | 59 (50%) |
| Clinical response at CT scana | |
| Response | 72 (60%) |
| Stabilization | 28 (24%) |
| Progression | 19 (16%) |
| Change in CEA level after chemotherapy (N = 113)b | |
| Response | 75 (66%) |
| Stabilization | 14 (12%) |
| Progression | 24 (21%) |
| Change in CA19.9 level after chemotherapy (N = 68)b | |
| Response | 48 (71%) |
| Stabilization | 8 (12%) |
| Progression | 12 (18%) |
| Hepatectomy | |
| PVE | 14 (12%) |
| Major hepatectomy (≥3 segments) | 62 (52%) |
| Mean no. of CLM at histopathology ± SD | 3 ± 3 |
| Mean maximum size of CLM at histopathology, mm ± SD | 44 ± 36 |
| Surgical margin statusc | |
| R0 | 71 (60%) |
| R1 | 43 (36%) |
| R2 | 4 (3%) |
| Postoperative mortality (≤2 months) | 1 (1%) |
| Postoperative complications | 43 patients (36%) |
| Hepaticd | 31 (26%) |
| Generale | 20 (17%) |
| Postoperative chemotherapy | 105 (88%) |
5-FU 5-fluorouracil, LV leucovorin, CT computed tomography, CEA carcinoembryonic antigen, CA carbohydrate antigen, PVE portal vein embolization, CLM colorectal liver metastases, SD standard deviation
aAccording to RECIST criteria22
bCutoff point 20%
cR0: complete surgical resection with a negative surgical margin at histopathology; R1: invaded surgical margins according to the pathologist; R2: macroscopic tumor remnant intraoperatively
dHepatic complications considered were: biliary leak/bilioma, hemorrhage, infected collection, noninfected collection, and transient liver insufficiency
eGeneral complications considered were: pulmonary, cardiovascular, urinary tract, infectious (other than local hepatic), and iatrogenic complications